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SIM ET AL.: Neurally Mediated Syncopal Syndrome: a Review of Investigations and Treatments. Neurally mediated
syncopal syndrome is an important cause of syncope affecting patients of all ages. Although the syndrome generally
is not life threatening, it may occur frequently and last for years. It can be very disabling too. A detailed history
taking, preferably with an eye-witness account, is important in the diagnosis of neurally mediated syncope. The
diagnosis and treatment of this syndrome has advanced further since the advent of tilt-table testing in 1986. The
different haemodynamic responses to tilt-table testing can distinguish vasovagal syncope from dysautonomic response
and may suggest specific approaches to therapy. The majority of patients can be treated effectively with education,
reassurance, and a simple increase in dietary salt. For those who required specific pharmacological interventions,
beta-blocker, midodrine, and fludrocortisone are most widely used. Permanent dual-chamber pacemakers should be
considered for selected patients who have frequent and medically refractory vasovagal syncope and a positive tilttable test with induced bradycardia.. (J HK Coll Cardiol 2000;8:148-158)
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Introduction
Patients presenting with syncope constitute 1-6%
of medical admissions in United State.1-3 The causes of
many of these patients' syncope are unexplained and
most remained symptomatic. 4,5 Neurally mediated
syncopal syndrome is an important cause of syncope
affecting patients of all ages - the mean age of patients
ranges from 30-70 years in most studies. Although
neurally mediated syncope generally is not life
threatening, it may occur frequently and last for years.
It can be very disabling too. Linzer et al6 reported that
patients with recurrent syncope have a level of
impairment similar to that in patients with severe
rheumatoid arthritis or chronic back pain and to
psychiatric inpatients. The diagnosis and treatment of
this syndrome has advanced a great deal since the advent
of tilt-table testing in 1986. This review focused on the
mechanism, clinical features, investigation and
treatment of patients who have vasovagal syncope.

Different Causes of Syncope
Table 1 lists the many possible causes of syncope.
A detailed account of syncope, the event leading to loss
of consciousness, and symptoms following the episode
is crucial to the diagnosis. An eye-witness account is
also very helpful particularly among the elderly subjects.
Sudden onset and rapid resolution of symptoms
with the presence of past medical history and risk factors
for ischaemic heart disease suggest a cardiac arrhythmia
and heart block as the cause of syncope. Associated
symptoms such as palpitation, dyspnoea, chest pain may
suggest a cardiac or pulmonary cause whilst patients
with prodromal symptoms of nausea, lightheadedness,
sweating, dimming of vision may have vasovagal
syncope. A lack of post-syncope drowsiness is typical
of vasovagal episode and witnesses often report that
the patient becomes extremely pale and the pulse may
be impalpable. Predisposing factors for vasovagal
syncope include fatigue, prolonged standing, heat,
venipuncture, and dental surgery. The history of
precipitants including pain, cough, micturition,
defaecation, swallowing are indicative of the diagnosis
of situational neurally mediated syncope whilst postural
change suggests orthostatic hypotension.
Syncope is rarely due to cerebrovascular disease
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unless there are accompanying focal neurological
deficits. Occasionally, transient posterior circulation
ischaemia can result in loss of consciousness and there
are usually brain stem signs present including diplopia,
vertigo, dysarthria, or hemiparesis. Seizures due to
either primary epilepsy or cerebral diseases (e.g.
aneurysms, tumours) can mimick vasovagal syncope
as the latter may have tonic-clonic movements or muscle
twitching. Prolonged convulsion with excessive
drowsiness after regaining consciousness, urinary
incontinence and tongue biting are more indicative of
seizures. However, akinetic seizure is even more
difficult to be distinguished from a syncopal spell. A
Table 1. Causes of syncope
Neurally mediated syncopal syndrome (Table 2)
Orthostatic and dysautonomic disturbances of blood pressure
control
Idiopathic orthostatic hypotension
Multisystem atrophy
Diabetic neuropathy
Drug induced orthostasis
Primary cardiac arrhythmias
Sinus node dysfunction
Atrioventricular conduction system disease
Paroxysmal superventricular tachycardia
Paroxysmal ventricular tachycardia
Structural cardiovascular or cardiopulmonary disease
Cardiac valvular disease
Acute myocardial infarction
Obstructive cardiomyopathy
Subclavian steal syndrome
Pericardial disease
Pulmonary embolism
Primary pulmonary hypertension
Cerebrovascular, neurologic, and psychiatric disease
Cerebral vascular disease
Seizure disorders
Narcolepsy
Hydrocephalus
Psychiatric disorders - panic attacks,
hysteria
Miscellaneous causes of syncope
Hyperventilation
Hypoglycaemia
Volume depleted syndrome - e.g. Addition's
hypoxaemia
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history of panic attack and hyperventilation points
towards to the diagnosis of psychiatric syncope.
The decision for further diagnostic tests depends
on whether there is evidence of underlying structural
heart disease based on the history, clinical examination
and ECG and/or echocardiography. In the former, tilt
table testing and the related autonomic function testing
are usually most productive. Various cardiac studies
will be more appropriate for those with suspected
structural heart disease.

Mechanism of Vasovagal Syncope
The neurally mediated syncopal syndromes, the
commonest being vasovagal syncope, encompass a
number of conditions that present with distinct clinical
scenarios but are believed to have many
pathophysiological similarities. Table 2 lists the
different entities of the syndrome.
In vasovagal syncope, it has been suggested that
the venous pooling in the lower extremities while in an
upright position leads to a reduction in cardiac output
and blood pressure that is sensed by arterial baroreceptor
located primarily in the aortic arch and carotid sinus.
The resultant increase in catecholamine levels,
combined with reduced venous return, leads to a
vigorously contracting volume-depleted ventricle. This
leads to the stimulation of mechanoreceptors found in

ventricles, atria, and pulmonary artery. These afferent
fibres (unmyelinated C-fibre) project centrally to the
medulla. The efferent part of the reflex results in vagal
stimulation leading to vasodalation and hypotension
(vasodepressor effect) or sympathetic withdrawal
leading to bradycardia (cardioinhibitory effect) or both
(Figure 1).7 This reflex pathway is often referred as
Bezold-Jarisch reflex.
A number of peripheral receptors similar to
ventricular mechanical receptors are found in various
organs (e.g. lung, bladder, gastrointestinal tract) which
may be responsible to many situational syncope.
However, in a recent publication, Liu et al 8

Table 2. lists the different entities of the neurally
mediated syncopal syndrome
NEURALLY MEDIATED SYNCOPAL SYNDROME
Vasovagal
Situational
Micturition
Cough
Swallowing
Defaecation
Exercise
Carotid sinus syncope
Neuralgias
Psychiatric disorder

TILT
HAEMORRHAGE
BRAIN SYSTEM
VENOUS RETURN
Small Ventricle
Vagal
Efferent

BP

Sympathetic
Withdrawal

REFLEX
HYPOTENSION
± BRADYCARDIA

CATECHOLS
SYNCOPE

Inotropy
Contractility

Figure 1. The mechanism of tilt or haemorrhage-induced vasovagal syncope.
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compared echocardographic measures of left ventricular
performance in 21 patients with unexplained syncope
who had either positive (n=10) or negative (n=11)
responses to a tilt-table test. After 5 minutes upright
tilt, patients who subsequently had a positive test had a
lower stroke volume, reduced end-systolic wall stress,
and reduced chamber function. This study implies that
LV hypercontractility is unlikely a universal trigger for
the activation of LV mechanoreceptors in the
pathogenesis of neurally mediated syncope. It is
however possible that the increase in wall stress or
contractility might occur more proximate to the syncope
event when echocardiographic recordings were not
obtained in this study.

table tests and therefore tilt-table testing exhibits a high
level of diagnostic specificity.13 It is about 90% on
passive tilting.14
The sensitivity generally increases with
pharmacological provocation whilst the specificity
decreases, although Raviele et al reported that the
addition of sublingual nitroglycerin increased the sensitivity
of the test while maintaining a high specificity.15
Apart from one report in which the reproducibility
of tilt table testing was 35%,16 most studies suggest that
the test reproducibility is in the 65-85% range whether
repeat testing is conducted on the same day or
substantially later.13

Protocol

Investigations
Tilt Table Testing
Tilt-table testing is a provocative test used to
determine a patient's susceptibility to neurally mediated
syncopal syndrome. Kenny et al first reported the use
of tilt table testing for investigating unexplained
syncope.10 The test has since become a widely accepted
tool in the clinical evaluation of patients presenting with
syncopal symptoms. The tests however are often not
performed following a standard protocol and are
supervised by inexperienced physicians. Deciding when
to terminate a test and determining whether a test is
positive or negative requires considerable experience
in some cases. These variables will obviously affect the
sensitivity and specificity of the test. Authors believed
the tilt-table testing should be led by a physician
specialising in this area who is able to supervise and
interpret the test and train others to do so. A suggested
protocol is described later in the article.

Sensitivity, Specificity and Reproducibility
In some studies of unexplained syncope, tilt-table
testing established the diagnosis of syncope in 40-70%
of patients.11,12 It is difficult to measure the sensitivity
of the tilt-table test for diagnosing neually mediated
syncope because there is as yet no accepted "gold
standard" for establishing the diagnosis against which
diagnostic procedures can be measured. Tilt-table test
sensitivity has been reported to range from 32% to 85%
when measured against a classic presentation.13 On the
other hand, very few control subjects had positive tilt-
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Tilt-table testing should be performed in a quite,
comfortable room with light dimmed. Patient should
be fasted for at least 3 hours before testing, or overnight
in preparation for early morning studies. 13 Many
investigators would avoid placement of intravenous or
intra-arterial lines.14 Concern has been expressed that
vascular instrumentation may alter specificity of the test
in older patients. Non-invasive beat-to-beat blood
pressure monitoring should be used17 and these include
Portapres and Colin 7000. The Portapres (Amsterdam
University) measures blood pressure using a
photoplethsmographic technique. The Colin 7000 (Colin
Medical Instruments, San Antonio, Texas) measures
blood pressure from the radial artery using arterial
tonometry.
Patient should be permitted to rest in the supine
position for about 20 minutes. The tilted angle is
between 60o to 80o, with 70o most commonly used.17
Tilt angles less than 60o do not seem to provide sufficient
orthostatic stress and result in a lower yield of positive
test responses in patients with syncope.18 The mean time
to syncope was approximately 25 minutes with a
standard deviation of 10 minutes in a few large series
of patients. The preference for a 45 minutes tilt-table
test is based on 2 standard deviations beyond the mean
time to syncope, and capturing 95% of patients who
are likely to develop syncope during a drug-free tilt.17
In general, a tilt test is deemed to be positive if
syncopal symptoms are reproduced due to hypotension
or bradycardia, or both as a result of the procedure. The
test may also be considered to be positive if syncope
occurs due to hypotension or bradycardia even though
the patient is unable to attest to reproduction of
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symptoms particularly among the elderly; or if
hypotension or bradycardia is of sufficient severity that
the associated presyncopal symptoms lead the attending
physician to believe that true syncope is inevitable.13
Currently, hypotension or bradycardia alone without
appropriate symptoms cannot be accepted as a positive
test. However, the attending physician may consider to
terminate the test if the excessive hypotension or
bradycardia is deemed potentially hazardous (e.g.
patients with cerebrovascular disease or significant
angina).

and titrate the isoproterenol dose to increase the heart
rate to 20-25% above the baseline, which usually results
in a dose of 1-3 microgram per minute.21
Indications for the tilt-table testing are listed in
Table 3.

Haemodynamic Responses to Tilt-Table Testing
Figure 2 illustrates the different haemodynamic
responses to tilt-table testing. 17 It is important to

Table 3. Indications for tilt-table testing

Pharmacological Provocation
Isoproterenol and nitroglycerin are the two most
commonly used agents. 19,20 Isoproterenol is a beta
agonist that increases heart rate and contractility, and it
is also a vasodilator. Nitroglycerin is principally a
vasodilator. Both agents increase the orthostatic stress
associated with upright posture because of their
vasodilatory effect.
Both sublingual nitroglycerin tablet (300-400
microgram) and spray (400 microgram) have been
used. The patient remains upright for another 20
minutes. 20 Isoproterenol however is administered
intravenously and the insertion of a venous line can
affect the autonomic system. The venous line should
therefore be placed well in advance of the tilt-table test.
The dosage of isoproterenol used varies in different
laboratories. Many start with 1 microgram per minute

1. Recurrent syncope or single syncopal episode in a high
risk patient, whether or not the medical history is
suggestive of neurally mediated (vasovagal) origin, and
• No evidence of structural cardiovascular disease (normal
ECG, echocardiography) Or
• Structural cardiovascular disease is present, but no other
causes of syncope have been excluded by appropriate
testing
2. Further evaluation of patients in whom an apparent cause
has been established (e.g. asystole, atrioventricular block),
but in whom demonstration of susceptibility to neurally
mediated syncope would affect treatment plans
3. Differentiating convulsive syncope from seizures
4. Evaluating patients (especially the elderly) with recurrent
unexplained falls
5. Assessing recurrent severe presyncopal symptoms

Haemodynamic Responses to Tilt-Table testing

Vsovagal
response

Type 1
Mixed

Type 2
Cardioinhibitory

Type 2A

Dysautonmic
response

Postural orthostatic
tachycardia syndrome
(POTS)

Type 3
Vasodepressor

Type 2B

Figure 2. Haemodynamic Responses to Tilt-Table testing.
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distinguish the haemodynamic pattern of vasovagal
syncope from those with dysautonomic response and
postural orthostatic tachycardia syndrome because the
different patterns may suggest specific approaches to
therapy.
Sutton et al 17 further divided the vasovagal
response into three sub-groups.
1. Mixed vasovagal syncope (type 1): The collapse of
blood pressure precedes a mild reduction in heart
rate. The drop of the heart rate does not fall below
40 beats per minute for more than 10 seconds.
2. Cardioinhibitory vasovagal syncope (type 2): It is
characterised by significant bradycardia during
collapse. The heart rate will drop below 40 beats
per minute for more than 10 seconds or asystolic
pause of more than 3 seconds. The drop in blood
pressure may precede (type 2A) or occur at the same
time as the bradycardia (type 2B).
3. Vasodepressor vasovagal syncope (type 3): This
refers to pure hypotenson with no bradycardia or only
a slight decrease in heart rate.
Patients with a dysautonomic response to headup tilt demonstrate a gradual and progressive decrease
in blood pressure with only a small or no significant
change in heart rate. This response represents a failure
of cardiovascular system to adapt to the haemodynamic
stress of upright posture.
Postural orthostatic tachycardia syndrome is
thought to be a milder form of chronic autonomic
dysfunction. These patients complain of excessive
fatigue, palpitation, exercise intolerence and recurrent
near-syncope and syncope. During tilt testing, these
patients demonstrate a sudden increase in heart rate by
more than 30 beats per minute in the first 5 minutes.
The heart rate can go up to 120 beats per minute before
a vasovagal type collapse with blood pressure decline
and some slowing from the peak heart beat.

Treatments of Vasovagal Syncope
Although vasovagal syncope generally is not life
threatening, it can be very disabling too.6 Most patients
with vasovagal syncope do not require specific
pharmacological intervention. Teaching patients to
recognise premonitory symptoms, avoid precipitating
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factors together with reassurance regarding the non-life
threatening nature of the condition may be very effective
in preventing recurrence. Salt supplements22 and
increased fluid in-take23 are also relatively safe and easy
to follow although there is not enough evidence to state
clearly that these treatments are beneficial. Several
studies have demonstrated that patients have
significantly less recurrence of syncope after a tilt-table
test, presumably due to the counselling and education
that were given after the tilt-tests.

Pharmacotherapy for Vasovagal Syncope
Beta-blocker
Beta-blockers have been widely used for
vasovagal syncope. These agents diminish the degree
of cardiac mechanoreceptor stimulation, probably by
blocking the circulating catecholamines. Several
nonrandomized studies and one randomizied placebocontrolled study have demonstrated the efficacy of betablocker therapy. In the placebo-controlled study,
Mahanonda et al 24 randomizied 42 patients with
vasovagal syncope to Atenolol and placebo and repeated
tilt-table testing one month later. 62% of patients in the
atenolol group had a negative tilt-table test compared
with 5% in the placebo group (p=0.0004). Moreover,
patients who received atenolol reported feeling better
than those who received placebo (71% vs 29%, p=0.02).
Beta-blockers have been evaluated during both
acute intravenous drug administration and longer-term
oral use in patients with vasovagal syncope. In a
nonrandomized study, Cox et al25 studied the use of
intravenous propanolol in 181 patients who had
vasovagal syncope induced in tilt-table testing and 163
(90%) had subsequent negative tilt-table tests. Of these,
125 patients were treated with oral propanolol, and at
follow-up tilt testing 118 (94%) patients no longer had
vasodepressor response.
Natale et al 26 studied 112 patients to assess if
intravenous beta-blocker can predict the efficacy of
long-term oral beta-blocker. In this study, all patients
were given intravenous esmolol and tilt-table testing
was then repeated. Regardless of the response during
esmolol, all patients were treated with metropolol. At
follow-up, 36 patients experienced symptoms relapse.
Four of them had negative tilt-table testing on esmolol,
whereas the remaining 32 did not respond to the acute
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infusion of esmolol. The authors concluded that acute
challenge with esmolol infusion appears to be an
accurate predictor of response to long-term use of betablocker. However, a small study (n=12) by Muller et
al 27 was unable to demonstrate that intravenous
metropolol could predict the effectiveness of long-term
oral beta-blocker therapy.
Metropolol, atenolol, propanolol and pindolol
have been the most frequently studied beta-blockers in
vasovagal syncope. Pindolol has intrinsic
sympathomimetic activity and diminishes the severity
of resting bradycardia in treated patients. There appears
to be sufficient evidence to demonstrate that betablockers are efficacious in the treatment of patients with
vasovagal syncope.

Fludrocortisone
Fludrocortisone is not associated with any serious
side effects and has been widely used to treat vasovagal
syncope and orthostatic hypotension particularly among
younger adults although there is no randomizied trials
to assess its efficacy. This agent increases sodium and
fluid retention. Some also reported that fludrocortisone
sensitised alpha-adrenergic receptors, increasing the
vasoconstrictive effects of norepinephrine28 and possibly
Midrodrine.
Two nonrandomizied studies have evaluated
fludrocortisone in paediatric patients. Grubb et al 29
studied 21 children who had vasovagal response in tilttable testing and found 10 children became tilt-table
testing negative after treating with flludrocortisone. At
the follow-up of around 20 months, 20 of 21 patients
had no further syncope. Scott et al30 randomizied 58
paediatric patients with positive tilt-table tests to receive
either atenolol or fludrocortisone. 48 (83%) reported
either no further syncope or the frequency had markedly
reduced. No difference of outcome was observed in the
2 treatment groups.

Midodrine and Other Vasoconstrictors
Midodrine produces both arteriolar constriction
and diminished venous pooling. Several nonrandomized
studies have demonstrated the benefit of using
Midodrine in patients with vasovagal syncope, but only
1 randomized placebo-controlled, 2x2 cross-over design
study has been published. In this study, Ward et al31
randomized 16 patients to Midodrine or placebo and
reported that midodrine provided an average of 7.3 more
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symptoms-free days than placebo (p<0.0001). Less
patients receiving midodrine had positive tilt-table
testing than those receiving placebo (p=0.01). Patients
on active treatment also felt better in all quality-of-life
domains than those on placebo. More recently, Mitro
et al32 evaluated, in a prospective nonradamized study,
the usefulness of midodrine in 41 patients with
vasovagal syncope. The efficacy was assessed by
repeated tilt testing in 1-2 weeks of therapy and by longterm follow-up. 39 of 41 (95%) had negative vasovagal
response in repeated tilt testing. Of these, 38 (97%)
remained free of syncope recurrence during a mean
follow-up period of 19 ± 9 months. Midodrine also
appears to be useful in patients refractory to other
standard treatment. 33 Side effects associated with
midodrine are usually not serious and these include scalp
itchiness, chills, urinary retention, and hypertension.
Another alpha-1 agonist, etilefrine, however was
found to be no benefit in the treatment of vasovagal
syncope in a prospective, randomized study.34 A number
of other alpha agonists including pseudoephedrine,
methyphenidate, and dextroamphetamines had been
studied at various times. However, the side effects, lack
of enough data and inconsistent effectiveness have
largely limited their use.

Selective Serotonin Reuptake Inhibitors (SSRI)
Activation of cerebral serotonin receptors inhibits
sympathetic nervous system activity and thereby
facilitates a vasodepressor response. Girolamo et al35
have reported the results of a randomized, double blind
placebe-controlled trial (p=68) of paroxetine in the
treatment of vasovagal syncope. The follow-up tilt tests
were negative after one month of treatment in 61.8% of
paroxetine group and 38.2% of the placebo group.
During the follow-up of average 8.9 months, syncope
was reported in 6 patients (17.6%) in the paroxetine
group as compared to 18 patients (52.9%) in the placebo
group (p<0.0001).
Several nonrandomized studies have also
reported the benefit of SSRI in the treatment of
vasovagal syncope. Grubb et al36 studied the effects
of fluoxetine in 16 patients who had failed standard
treatments. 13 of these 16 patients tolerated long-term
therapy, and 7 (44%) remained free from syncope
during 19±9 months of follow-up. Grubb et al
similarly demonstrated the benefit of sertraline in an
uncontrolled study of 17 patients. 3 were intolerant
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Role of Pacing in the Treatment of
Vasovagal Syncope

of therapy, and 5 remained til testing positive. Of
the remaining tilt testing negative patients, all were
reported to have remained asymptomatic during 12
+/- 5 months of follow-up. Tanden et al37 on the other
hand reported a small series of three patients who
experienced exacerbation of vasovagal syncope
during treatment with sertraline.
There are overall sufficient data to conclude that
SSRI are of value in the treatment of vasovagal syncope
for those who can tolerate the medication.

The rationale for pacing patients with vasovagal
syncope is to prevent bradycardia and compensate the
transient decline of cardiac output in case of a collapse
of blood pressure.

Disopyramide

Pacing During Tilt Table Testing

The mechanisms of disopyramide, a class IA
antiarrhythmic agent, in treating vasovagal syncope
include its negative inotropic, anticholinergic, and direct
peripheral vasoconstrictive effects. In a randomized
placebo-controlled study, Morillo et al38 found that
syncope recurrence was comparable in both
disopyramide and placebo treated group. Other
nonrandomized studies however supported the clinical
utility of disopyramide.39,40 Investigators have also found
that disopyramide is useful in patients not responded to
beta-blockers.26
Disopyramide has significant side effects and
potential for proarrhythmia including Torsade de
Pointes. Because of the side effects and the conflicting
data regarding its efficacy, disopyramide should not be
used as a first-line therapy for vasovagal syncope.

Several investigators examined the benefit of
pacing during tilt table testing in patients who previously
had a positive tilt-table test with marked bradycardia.
Fitzpatick et al44 undertook tilt-table testing on three
consecutive days in 10 patients with predominately
cardioinhibitory vasovagal episodes. The studies
undertaken in the first two days acted as control and
evidence of reproducibility of syncope. On the third day,
tilt testing was repeated, this time using dual chamber
(temporary) pacing. The protocol used a hysteresis mode
with a base rate 50 beats/minute (bpm) and subsequent
intervention at rate of 90 bpm.
This study showed that pacing prevented syncope
in 5 of 7 patients, their cardiac output doubled, and their
rate of progression to syncope slowed. Two other
groups, Samoil et al45 and Sra et al,46 undertook similar
studies and also showed benefit of pacing during tilttable testing. In contrast, El-Bedawi et al47 found no
benefit from dual-chamber pacing in 9 patients with
vasovagal syncope.

Other Pharmacological Agents
Many pharmacological agents have been reported
to be useful, but for the most parts, the evidence is very
limited. Scopolamine, an anticholinergic agent, has been
considered to be beneficial in the treatment of vasovagal
syncope. Lee et al41 randomized 60 patients with tiltinduced syncope to scopolamine or placebo and found
no clear evidence that scopolamine is more useful than
placebo. Another anticholinergic agent, propantheline
bromide, had been shown to have a positive effect on
prevention of vasovagal recuerrence in 2 small
nonrandomized studies. 42,43 Other agents include
theophylline and clonidine. They had not been
investigated by randomized placebo-controlled studies,
a few small nonrandomozed studies showed that they
might be useful in preventing tilt-induced syncope. The
high intolerance of theophylline also limited its clinical
usefulness.
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Evidence for the Benefits of Pacing

Historically Controlled Studies of Permanent
Pacing
Table 4 summaries the three historically
controlled trials of permanent pacing for vasovagal
syncope. These studies consistently showed that, after
insertion of a permanent pacemaker, most patients either
stopped fainting or had far fewer faints.
All patients recruited in these studies had
significant syncopal symptoms (at least two fainted
episodes per year) and a positive tilt-table test with
induced bradycardia of heart rate usually less than 60
bpm. Dual-chamber pacemakers were used and three
different pacing modes employed. Petersen et al used
pacing with rate hysteresis setting the sensor rate of
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Table 4. Historically controlled studies of permanent pacing
Study
Petersen et al48
Benditt et al49
Sheldon et al50

n
31
28
12

Patient symptoms
Fainted twice yearly
Fainted once monthly
Three faints per month

Pacing modes
Rate hysteresis
Rate dropping response
Rate smoothing

Results
89% improved; 62% stopped fainting
78% stopped fainting
93% improved; 50% stopped fainting

All results were statistically significant

40-50 bpm and a pacing rate of 85-100 bpm. Benditt et
al used a rate-drop responsiveness pacing system. In
this mode, the pacemaker sensed small decreases in
heart rate around 10-20 bpm, then paces at a high rate
of 100-110 bpm for 1-2 minutes. Sheldon et al used
pacemaker with autonomic rate smoothing.

Randomizied Controlled Study
In the North American Vasovagal Pacemaker
Study (VPS I),51 patients were randomized to receive a
pacemaker with autonomic rate-drop responsiveness or
the best medical therapy according to the treating
physician. The study enrolled 54 patients who had
fainted more than six times before tilt-table testing, or
if they had fainted within the first year after a positive
tilt-table test. They all had a pre-defined bradycardia
during tilt-table testing (heart rate less than 60 bpm or
heart rate 70-80 if isoprenaline provocation was used).
The study demonstrated a clear benefit for those
randomized to pacing, who had a 91% reduction in the
risk of developing recurrent syncope.

Patient Selection for Pacing and Pacing Modes
All three historically controlled studies and one
randomised controlled study selected patients who
had a positive tilt-table test with a pre-defined
bradycardia (usually less than 60 bpm) and frequent
syncopal attacks (at least 6 syncopal attacks in the
VPS I). However, there is no evidence to confirm
that patients with bradycardia induced by tilt-table
testing also have clinical bradycardia. The on-going
Vasovagal Pacemaker Study II (VPS II) recruited
patients with frequent vasovagal syncope and a
positive tilt-table test with or without bradycardia.
The study may answer the question whether pacing
benefit patients who had no induced bradycardia
during tilt-table testing.
Dual-chamber pacing was shown to be superior
to ventricular pacing in preventing syncope in a small,

J HK Coll Cardiol, Vol 8

double-blinded, cross-over, randomized study by
Mcleod et al.52 Dual-chamber pacing with three pacing
modes were assessed clinically - rate hysteresis, ratedrop responsiveness and rate smoothing - and all were
shown to be effective. A small randomized study by
Ammirali et al53 suggested that DDD pacing with ratedrop response is superior to DDI pacing with rate
hysteresis. The VPS II study is also assessing whether
pacing with rate-drop sensing is superior to an escaped
rate of 45 bpm. There is still debate regarding the
optimal pacemaker intervention rate. High rate pacing
intervention (>120 bpm) may be better than standard
rate intervention (80-90 bpm) in ameliorating symptoms
and/or aborting syncope.
Alternate sensing strategies, such as QT intervals,
right ventricular pressure, core temperature, and indices
of contractility, are under investigated. The theory
behind contractility sensors is that vasovagal syncope
may be preceded by small but significant increases in
contractility due to a sympathetic surge. These
pacemakers increase pacing rate in response to rises in
contractility.
Reversing the decline in the heart rate only deals
with one aspect of the underlying pathophysiological
changes of vasovagal syncope. Pacing should not been
seen as the alternative to pharmacological intervention.
Combining with, for example, a peripheral
vasoconstrictor (midodrine) or intravascular fluid
expander (fludrocortisone) with pacing may achieve
better results.
There is also potential concern with pacing those
with vasovagal syncope particularly amongst the
younger patients, not least of which is the need for
periodic system replacement. Such reluctance does not
necessarily apply to the older patients with chronotropic
incompetence.
According to the currently available studies data,
dual-chamber pacemakers should be considered for
selected patients who have frequent and medically
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refractory vasovagal syncope and positive tilt-table test
with induced bradycardia. The results of the VPS II
(completed by 2002) may provide more information
about which pacing modes (rate-drop responsiveness
or escaped rate) is superior and whether patients with
no bradycardia during tilt-table test may also benefit
from pacing.

Conclusion
A detailed history taking, preferably with an eyewitness account, is important in the diagnosis of neurally
mediated syncope. Despite the relatively low sensitivity,
tilt-table testing at present remains the "gold standard"
for diagnosing neurally mediated syncope and should
be used in selected cases of unexplained syncope
particularly in patients with no underlying structural
cardiac problems. The different haemodynamic
responses to tilt-table testing may suggest specific
approaches to therapy.
Education and counselling are the initial steps
in managing patients with vasovagal syncope. For
those who required specific pharmacological
interventions, beta-blocker, midodrine, and serotonin
re-uptake inhibitor have been proven to be effective
in treating vasovagal syncope in randomized placebocontrolled studies. Despite the lack of a placebocontrolled randomized study, there is a wealth of
favourable clinical experience with fludrocortisone
in treating vasovagal syncope and orthostatic
hypotension. These four agents can therefore be used
as the first-line therapy. Disopyramide and
anticholinergic agents may have a place for those who
do not respond to the first-line treatment. Permanent
dual-chamber pacemakers, with either rate hysteresis
or rate-drop pacing mode, should be considered for
selected patients who have frequent and medically
refractory vasovagal syncope and a positive tilt-table
test with induced bradycardia.
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